Cowen analyst Chris Shibutani reiterated an Outperform rating on Syndax Pharmaceuticals (NASDAQ: SNDX) announced that it has hit ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE